Câncer de mama no ESMO 2022

Notas do episódio

Os estudos em câncer de mama que concentraram as atenções no encontro anual da Sociedade Europeia de Oncologia Médica (ESMO 2022) estão em pauta no PODCAST ONCONEWS, com apresentação dos médicos Daniel Gimenes e Silvio Bromberg. Entre os destaques estão os resultados finais do estudo de Fase 3 DATA, que avalia a inibição estendida da aromatase adjuvante após terapia endócrina sequencial; e trabalho que buscou identificar subgrupos de câncer de mama HER2-positivo biologicamente associados ao prognóstico após trastuzumabe adjuvante no estudo ALTTO. Ouça. Referências: 1. V.C.G. Tjan-Heijnen, S.W.M. Lammers, S.M.E. Geurts, I.J.H. Vriens, A.C.P. Swinkels, C.H. Smorenburg, M. van der Sangen, J.R. Kroep, H. de Graaf, A.H. Honkoop, F.L.G. Erdkamp, W.K. de Roos, S.C. Linn, A.L.T. Imholz. Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial. ESMO Congress 2022, Abstract 133O. https://oncologypro.esmo.org/meeting-resources/esmo-congress/extended-adjuvant-aromatase-inhibition-after-sequential-endocrine-therapy-final-results-of-the-phase-iii-data-trial 2. Joaquin Garcia, M. Rediti, D. Venet, S. Majjaj, R. Kammler, M.A. Colleoni, S. Loi, G. Viale, M.M. Regan, F. Rothé, C. Sotiriou. Differential benefit of low-dose cyclophosphamide and methotrexate maintenance chemotherapy among TNBC subtypes in the context of the IBCSG 22-00 study. ESMO Congress 2022, Abstract 136MO https://oncologypro.esmo.org/meeting-resources/esmo-congress/differential-benefit-of-low-dose-cyclophosphamide-and-methotrexate-maintenance-chemotherapy-among-tnbc-subtypes-in-the-context-of-the-ibcsg-22-00-s 3. R.A. Badwe, V. Parmar, N.S. Nair, R. Hawaldar, S. Joshi, S. Pawar, G. Kadayaprath, B. Borthakur, S. Rao, S. Pandya, S. B, P. Chitale, R. Neve, C. Harris, A. Srivastava, S. Siddique, V. Vanmali, A. Dewade, V. Gaikwad, S. Gupta. Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast câncer. ESMO Congress 2022, Abstract 137MO https://oncologypro.esmo.org/meeting-resources/esmo-congress/effect-of-peri-tumoral-infiltration-of-local-anaesthetic-prior-to-surgery-on-survival-in-early-breast-cancer 4. M. Rediti, D. Venet, A. Joaquin Garcia, D. Agbor-tarh, M. Maetens, D. Vincent, S. Majjaj, S. El-Abed, M.C. Liu, S. Di Cosimo, M. Piccart, L. Pusztai, S. Loi, R.F. Salgado, G. Viale, F. Rothé, C. Sotiriou. Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial. ESMO Congress 2022, Abstract 139MO https://oncologypro.esmo.org/meeting-resources/esmo-congress/identification-of-biologically-driven-her2-positive-breast-cancer-subgroups-associated-with-prognosis-after-adjuvant-trastuzumab-in-the-altto-trial --